Please assess the completion status of the following clinical trial:

Trial Title: Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥ 18 years of age~* Documented diagnosis of myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML), white blood cells (WBC) ≤ 13,000 /mm\^3, World Health Organization (WHO) that meets International Prognostic Scoring System (IPSS) criteria for low or intermediate-1 risk disease~* Anemia, Hemoglobin (Hgb) ≤ 9.0 g/dL or ≥ 2 units of Red Blood Cells (RBCs) within 84 days~* No response or loss of response to Erythropoiesis-Stimulating Agents (ESAs) or erythropoetin (EPO) \> 500 mU/ml~* Eastern Cooperative Group (ECOG) score ≤2.~* Creatinine \< 1.5 \* Upper Limit of the Normal (ULN)~* Total bilirubin ≤3.0 mg/dL~* Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT) \& Alanine Aminotransferase (ALT)/Serum Glutamic Pyruvic (SGPT) ≤3.0 \* Upper Limit of Norma (ULN)~* Free of metastatic malignancy (other than MDS) for ≥2 years~* Highly effective methods of birth control for females and males~Exclusion Criteria:~* Chromosome 5q deletion~* Pregnant or breast feeding women and males who do not agree to use condom during the sexual contact with females of childbearing potential~* Major surgery within 30 days~* Incomplete recovery or incomplete healing of wounds from previous surgery~* Heart failure ≥3 (New York Heart Association (NYHA))~* Thromboembolic or myocardial infarction event within 6 months~* Concurrent anti-cancer cytotoxic chemotherapy~* History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant protein~* Known positive for Human Immunovirus (HIV) or infectious Hepatitis type C or active infectious Hepatitis type B~* Clinically significant anemia unrelated to MDS~* Thrombocytopenia (\<30,000/uL)~* Uncontrolled hypertension~* Treatment with another investigational drug or device within 28 days prior to Day 1~* Prior exposure to sotatercept (ACE-011)~* Any serious medical condition, lab abnormality or psychiatric illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sotatercept 0.1 mg/kg (Type: EXPERIMENTAL): Sotatercept 0.1 mg/kg
- Sotatercept 0.3 mg/kg (Type: EXPERIMENTAL): Sotatercept 0.3 mg/kg
- Sotatercept 0.5 mg/kg (Type: EXPERIMENTAL): Sotatercept 0.5 mg/kg
- Sotatercept 1.0 mg/kg (Type: EXPERIMENTAL): Sotatercept 1.0 mg/kg
- Sotatercept 1.5 mg/kg (Type: EXPERIMENTAL): Sotatercept 1.5 mg/kg
- Sotatercept 2.0 mg/kg (Type: EXPERIMENTAL): Sotatercept 2.0 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).